Hypomethylating agents (HMAs) are the current standard treatment for newly diagnosed high-risk MDS and offer an overall response rate (ORR) of 17%–77% in patients with TP53-mutated MDS, with International Working Group complete response (CR) in 10–25% of patients and a median overall survival (OS) of 8.2–12.4 months (15, 16). This evidence concerns the gene TP53 and myelodysplastic syndrome.